Enliven Therapeutics, Inc.

NasdaqGS ELVN

Enliven Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 999.66 M

Enliven Therapeutics, Inc. Market Capitalization is USD 999.66 M on January 14, 2025, a 97.38% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Enliven Therapeutics, Inc. 52-week high Market Capitalization is USD 1.44 B on November 06, 2024, which is 44.43% above the current Market Capitalization.
Enliven Therapeutics, Inc. 52-week low Market Capitalization is USD 478.39 M on January 17, 2024, which is -52.15% below the current Market Capitalization.
Enliven Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 1.04 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGS: ELVN

Enliven Therapeutics, Inc.

CEO	Mr. Samuel S. Kintz M.B.A.
IPO Date	March 12, 2020
Location	United States
Headquarters	6200 Lookout Road
Employees	46
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Key trends

Past 5 years